BMP7 Antibody #4693
- WB
- IP
Supporting Data
| REACTIVITY | M |
| SENSITIVITY | Transfected Only |
| MW (kDa) | 49 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly99 of mouse BMP7. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Bone morphogenetic proteins (BMPs) were first identified as molecules that can induce ectopic bone and cartilage formation (1,2). BMPs belong to the TGF-β superfamily, playing many diverse functions during development (3). BMPs are synthesized as precursor proteins and then processed by cleavage to release the C-terminal mature BMP. BMPs initiate signaling by binding to a receptor complex containing type I and type II serine/threonine receptor kinases that then phosphorylate Smad (mainly Smad1, 5, and 8), resulting in the translocation of Smad into the nucleus. BMP was also reported to activate MAPK pathways in some systems (3,4).
BMP7, also known as osteogenic protein-1 (OP-1), is found to be upregulated in some cancer cells (5-7), and may play a role in cancer metastasis (7-9).
- Wang, E.A. et al. (1988) Proc Natl Acad Sci USA 85, 9484-8.
- Wozney, J.M. et al. (1988) Science 242, 1528-34.
- Kawabata, M. et al. (1998) Cytokine Growth Factor Rev 9, 49-61.
- Nohe, A. et al. (2004) Cell Signal 16, 291-9.
- Yang, S. et al. (2005) Cancer Res 65, 5769-77.
- Alarmo, E.L. et al. (2006) Genes Chromosomes Cancer 45, 411-9.
- Motoyama, K. et al. (2008) Ann Surg Oncol 15, 1530-7.
- Buijs, J.T. et al. (2007) Cancer Res 67, 8742-51.
- Buijs, J.T. et al. (2007) Am J Pathol 171, 1047-57.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.